Search

Displaying results 6591 - 6600 of 9716 in total
  1. Drug

    IGN301

    go.drugbank.com/drugs/DB05117
    Experimental

    IGN301 is a cancer vaccine based on an anti-idiotypic antibody which provokes an immune response to Lewis Y. … Lewis Y is a carbohydrate molecule expressed on the surface of tumor cells of epithelial origin (e.g. lung, intestinal, breast, prostate or ovarian cancers).

  2. Drug

    AT1391

    go.drugbank.com/drugs/DB05120
    Experimental

    AT1391 is a daily insulin skin patch designed to provide continuous basal levels of insulin for patients with diabetes.

  3. Drug

    1D09C3

    go.drugbank.com/drugs/DB05121
    Experimental

    1D09C3, a monoclonal antibody against lymphoid cancers, is an anti-MHC (major histocompatibility complex) class II monoclonal antibody. … selectively killing activated, proliferating MHC class II-positive tumor cells, which include those in B-cell and T-cell lymphomas. 1D09C3 has been shown to induce programmed cell death and does not require a

  4. Drug

    SC12267

    go.drugbank.com/drugs/DB05125
    Investigational

    SC12267 is a novel, small molecule agent from the class of DMARDs (disease modifying anti-rheumatic drug) for the therapy of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis.

  5. Drug

    PYM50018

    go.drugbank.com/drugs/DB05126
    Experimental

    When administered orally to a transgenic pre-clinical model of ALS, PYM50018 delays the loss of muscle strength and extends survival time. … PYM50018 is a patented, orally active, neuroprotective and neuroregenerative compound. It is developed for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease).

  6. Drug

    INCB3284

    go.drugbank.com/drugs/DB05130
    Experimental

    INCB3284 is a CCR2 antagonist for Inflammation-driven Diseases.

  7. Drug

    VP025

    go.drugbank.com/drugs/DB05133
    Experimental

    It is considered to be a systemic anti-inflammatory and neuroprotective agent. … VP025, a novel drug formulation based on phospholipid microparticles incorporating phosphatidylglycerol, can inhibit neuroinflammation.

  8. Drug

    AdPEDF

    go.drugbank.com/drugs/DB05138
    Experimental

    AdPEDF is under development for the treatment of wet age-related macular degeneration (AMD). It has been shown to rapidly elevate the intraocular AdPEDF protein levels in the eye, inhibit abnormal blood vessel growth, and cause abnormal ...

  9. Drug

    OXI-4503

    go.drugbank.com/drugs/DB05143
    Investigational

    OXI-4503 is a solid. OXI-4503 blocks and destroys tumor vasculature, resulting in extensive tumor cell death and necrosis. … OXI-4503 (combretastatin A1 di-phosphate / CA1P) is a unique and highly potent, dual-mechanism vascular disrupting agent (VDA).

    Synonyms: Combretastatin A-1 bis(phosphate)
  10. Drug

    PEV3A

    go.drugbank.com/drugs/DB05144
    Investigational

    PEV3A is a prophylactic malaria vaccine that acts against various stages of the disease. It is a two-component vaccine that contains the virosome formulated peptide mimetics PEV301 and PEV302.